<DOC>
	<DOCNO>NCT01922284</DOCNO>
	<brief_summary>UKHVC Spoke 003 randomised Phase I , two centre study explore impact shorten vaccination regimen use deoxyribonucleic acid ( DNA ) ( CN54ENV ZM96GPN ) , Modified Vaccinia Ankara - C ( MVA-C ) CN54rgp140 adjuvanted glucopyranosyl lipid A adjuvant - aqueous form ( GLA-AF ) . The study population 40 healthy male female volunteer 18 45 year old low risk HIV infection recruit . Study participant immunise trial immunogen : - 8mg DNA : one plasmid encode gag-pol-nef polypeptide derive 96ZM651-8 clone one plasmid encode gp140 env derive clade C 97CN54 - 1.108 TCID50 MVA-C ( nominal titre ) express gag-pol-nef gp120 env proteins derive clade-C 97CN54 - 100ug CN54rgp140 , trimeric recombinant envelope protein derive clade C 97CN54 - 5ug GLA-AF , aqueous glucopyranosyl lipid A adjuvant All immunisation administer intramuscular route ( IM ) . CN54gp140 GLA mix together administration , immunogen deliver combination regimen</brief_summary>
	<brief_title>Investigating Immunisation Strategies DNA , MVA CN54rgp140 Adjuvanted With GLA-AF Maximise Antibody Responses</brief_title>
	<detailed_description>This phase I study explore safety potency five HIV vaccine healthy volunteer . The main aim see whether three five vaccine give together rather one , five rather seven set vaccination course shorten eight week . All volunteer receive three injection first two vaccine ( DNA plasmid ) half randomly assign receive two injection second ( MVA-C ) subsequent vaccine ( CN54rgp140 mixed GLA-AF ) visit two injection MVA-C follow two CN54rgp140 mixed GLA-AF . The investigator interested ensure vaccine safe also immune response two group volunteer similar . The three vaccine show stimulate immune response specific part HIV virus none infectious . The first vaccine consist two DNA plasmid . When injected muscle cell small part HIV virus encode DNA produce recognise immune system . The second vaccine MVAC , derive vaccinia virus modify divide . The virus ( Modified Vaccinia Ankara ( MVA ) ) actually express portion HIV DNA result amplification responses see . The third vaccine synthetically produce component HIV viral outer coat administer additive show greatly enhance particular type immune response recently show play role protection infection</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Man woman age 18 45 year day screen 2 . Available followup duration study ( ~10 month enrolment ) 3 . At low risk HIV willing remain duration study define : history inject drug use previous ten year gonorrhoea syphilis last six month high risk partner ( e.g . inject drug use , HIV positive partner ) either currently within past six month unprotected anal intercourse last six month , outside relationship regular partner know HIV negative unprotected vaginal intercourse last six month outside relationship regular known/presumed HIV negative partner 4 . Willing undergo HIV test 5 . Willing undergo genital infection screen indicate sexual history 6 . If heterosexually active female , use effective method contraception partner IUCD/IUS ( combine oral contraceptive pill ; injectable implanted contraceptive ; consistent record condom use ; physiological anatomical sterility self partner ) 14 day prior first vaccination 4 month last , willing undergo urine pregnancy test prior vaccination 7 . If heterosexually active male , use effective method contraception partner first day vaccination 4 month last vaccination 8 . Agree abstain donate blood three month end participation trial , longer necessary 9 . Registered general practitioner ( GP ) least past three month 10 . Satisfactory response receive GP randomisation 11 . Willing able give write informed consent 1 . Pregnant lactate 2 . Presence IUCD ( intrauterine contraceptive device ) /IUS ( intrauterine system ) 3 . Clinically relevant abnormality history examination include history grandmal epilepsy , seizure disorder history prior seizure severe eczema liver disease inadequate hepatic function skin condition may interfere trial assessment injection site haematological , metabolic , gastrointestinal cardiopulmonary disorder uncontrolled infection ; toxic shock syndrome ; autoimmune disease , immunodeficiency use immunosuppressives precede 3 month 4 . Known hypersensitivity component vaccine formulation use trial , severe multiple allergy drug pharmaceutical agent 5 . History severe local general reaction vaccination define 1. local : extensive , indurated redness swell involve major circumference arm , resolve within 72 hour 2. general : fever &gt; = 39.5Â°C within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal oedema ; collapse ; convulsion encephalopathy within 72 hour 6 . Receipt live attenuate vaccine within 60 day vaccine within 14 day enrolment 7 . Receipt experimental vaccine contain HIV antigen time past 8 . Receipt blood product immunoglobin within 4 month screen 9 . Participation another trial medicinal product , complete less 30 day prior enrolment 10 . HIV 1 2 positive indeterminate screen 11 . Positive hepatitis B surface antigen , hepatitis C antibody serology indicate active syphilis require treatment 12 . Grade 1 routine laboratory parameter . Hyperbilirubinaemia consider exclusion criterion confirm conjugated bilirubinaemia 13 . Unable read speak English fluency level adequate full comprehension procedure require participation consent . 14 . Unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunisation</keyword>
	<keyword>DNA</keyword>
	<keyword>Adverse event</keyword>
	<keyword>MVA-C</keyword>
	<keyword>GLA-AF</keyword>
	<keyword>Antibody</keyword>
</DOC>